Promising neoadjuvant antitumor activity for patients with muscle-invasive bladder cancer
Enfortumab vedotin is an antibody-drug conjugate directed to Nectin-4, that is highly expressed in urothelial cancer. In this MEDtalk, Professor Daniel P. Petrylak of Yale Cancer Center presents data from the EV-103 study. It shows promising antitumor activity in patients with muscle-invasive bladder cancer, ineligible for cisplatin.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.